E therapeutics : Results of Annual General Meeting and Appointment of Jeremy Punnett to the Board of Directors

Results of Annual General Meeting and Appointment of Jeremy Punnett to the Board of Directors

London, UK, 16 July 2024 - e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, announces that at its Annual General Meeting held earlier today, all resolutions, as set out in the Notice of Meeting, were duly passed.

The Annual General Meeting votes were as follows:

Resolution	Votes For	%	Votes Against	%	Abstentions	Resolution Result
Ordinary Resolution 1	479,716,672	100	0	0	0	Passed
Ordinary Resolution 2	479,716,672	100	0	0	0	Passed
Ordinary Resolution 3	479,716,672	100	0	0	0	Passed
Ordinary Resolution 4	479,716,672	100	0	0	0	Passed
Ordinary Resolution 5	479,716,672	100	0	0	0	Passed
Ordinary Resolution 6	479,716,672	100	0	0	0	Passed
Special Resolution 7	479,716,672	100	0	0	0	Passed

In addition, the Company is pleased to announce the appointment of Jeremy Punnett to the Board of Directors. Jeremy is a fund manager at M&G Investment Management Limited ("M&G") where he is responsible for pre-IPO and growth equity investing, having previously worked on corporate governance and public and private transactions for the public equities business. Since joining M&G in 2019, Jeremy has been involved in numerous private and public investment transactions. He led the most recent investment by M&G in e-therapeutics and was involved in the previous private placement.

Before joining M&G, Jeremy began his career as a strategy consultant for KPMG and PA Consulting, later working for a private shipowner in a variety of strategic roles and running a listed oil and gas shipping investment trust. Jeremy is a Chartered Financial Analyst and holds an M.Sc in Economic History from the London School of Economics, an MBA from Manchester Business School, and an M.Com in International Business from the University of Auckland.

Share